# A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

> **NCT02611323** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 133 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Rituximab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02611323
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2022-08-04
- **Final completion:** 2022-08-04
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611323, "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02611323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*